Nutriband Inc. has released its Q2 2026 financial and operational update, highlighting meaningful revenue growth and major progress in the development of AVERSA™ Fentanyl - the company's lead abuse-deterrent transdermal patch.
Contract manufacturing revenue rose 50% YoY, driven by the expansion of kinesiology tape production through Pocono Pharma.
The company reported $0.6M in revenue and closed the quarter with $6.9M in cash.
A critical FDA Type C meeting is scheduled for September 18, 2025, to discuss the upcoming Phase 1 clinical trial for AVERSA™ Fentanyl.
This innovative patch combines a proven opioid with Nutriband's proprietary abuse-deterrent technology and requires only a single Phase 1 study to demonstrate lower abuse potential.
The company plans to expand the AVERSA platform to Buprenorphine, a key therapy for opioid dependence.
Analysts maintain an Outperform rating with a $15 target price, citing the strong strategic focus and growth in contract revenues to support clinical advancement.